Clinical trial
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant…
NCT00041587 · INSYS Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00041587 |
|---|---|
| Title | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma |
| Official title | Pre-operative IL13-PE38QQR Infusion in Patients With Recurrent or Progressive Supratentorial Malignant Glioma: A Phase I/II Study |
| Lead sponsor | INSYS Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma |
| Intervention type | Drug, Procedure |
| Interventions | IL13-PE38QQR, targeted fusion protein therapy, surgery |
| Enrollment | 80 |
| Start date | Jul 1, 2002 |
| Primary completion | Jun 1, 2006 |
| Completion | Jul 1, 2007 |
| First posted | Jul 12, 2002 |
| Last update posted | Jun 6, 2011 |
| Countries | Germany, Israel, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: